These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15691023)

  • 21. Purification, kinetics, inhibitors and CD for recombinant β-amyrin synthase from Euphorbia tirucalli L and functional analysis of the DCTA motif, which is highly conserved among oxidosqualene cyclases.
    Ito R; Masukawa Y; Hoshino T
    FEBS J; 2013 Mar; 280(5):1267-80. PubMed ID: 23294602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereospecific syntheses of trans-vinyldioxidosqualene and 3-hydroxysulfide derivatives, as potent and time-dependent 2,3-oxidosqualene cyclase inhibitors.
    Viola F; Balliano G; Milla P; Cattel L; Rocco F; Ceruti M
    Bioorg Med Chem; 2000 Jan; 8(1):223-32. PubMed ID: 10968281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of the channel constriction allowing the access of the substrate to the active site of yeast oxidosqualene cyclase.
    Oliaro-Bosso S; Caron G; Taramino S; Ermondi G; Viola F; Balliano G
    PLoS One; 2011; 6(7):e22134. PubMed ID: 21811565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of 2,3-oxidosqualene cyclase and sterol biosynthesis by 10- and 19-azasqualene derivatives.
    Viola F; Brusa P; Balliano G; Ceruti M; Boutaud O; Schuber F; Cattel L
    Biochem Pharmacol; 1995 Sep; 50(6):787-96. PubMed ID: 7575639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Binding structures and potencies of oxidosqualene cyclase inhibitors with the homologous squalene-hopene cyclase.
    Lenhart A; Reinert DJ; Aebi JD; Dehmlow H; Morand OH; Schulz GE
    J Med Chem; 2003 May; 46(11):2083-92. PubMed ID: 12747780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel pyrrole- and 1,2,3-triazole-based 2,3-oxidosqualene cyclase inhibitors.
    Watanabe T; Umezawa Y; Takahashi Y; Akamatsu Y
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5807-10. PubMed ID: 20728352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highly improved antiparasitic activity after introduction of an N-benzylimidazole moiety on protein farnesyltransferase inhibitors.
    Bosc D; Mouray E; Cojean S; Franco CH; Loiseau PM; Freitas-Junior LH; Moraes CB; Grellier P; Dubois J
    Eur J Med Chem; 2016 Feb; 109():173-86. PubMed ID: 26774924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2,3-Oxidosqualene cyclase: from azasqualenes to new site-directed inhibitors.
    Cattel L; Ceruti M; Balliano G; Viola F; Grosa G; Rocco F; Brusa P
    Lipids; 1995 Mar; 30(3):235-46. PubMed ID: 7791532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 19-Azasqualene-2,3-epoxide and its N-oxide: metabolic fate and inhibitory effect on sterol biosynthesis in Saccharomyces cerevisiae.
    Milla P; Viola F; Ceruti M; Rocco F; Cattel L; Balliano G
    Lipids; 1999 Jul; 34(7):681-8. PubMed ID: 10478925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug design based on biosynthetic studies: synthesis, biological activity, and kinetics of new inhibitors of 2,3-oxidosqualene cyclase and squalene epoxidase.
    Cattel L; Ceruti M; Balliano G; Viola F; Grosa G; Schuber F
    Steroids; 1989; 53(3-5):363-91. PubMed ID: 2678608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Arylpiperidines as a new class of oxidosqualene cyclase inhibitors.
    Keller M; Wolfgardt A; Müller C; Wilcken R; Böckler FM; Oliaro-Bosso S; Ferrante T; Balliano G; Bracher F
    Eur J Med Chem; 2016 Feb; 109():13-22. PubMed ID: 26745812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and inhibition studies of sulfur-substituted squalene oxide analogues as mechanism-based inhibitors of 2,3-oxidosqualene-lanosterol cyclase.
    Stach D; Zheng YF; Perez AL; Oehlschlager AC; Abe I; Prestwich GD; Hartman PG
    J Med Chem; 1997 Jan; 40(2):201-9. PubMed ID: 9003518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional characterization and localization of Pneumocystis carinii lanosterol synthase.
    Joffrion TM; Collins MS; Sesterhenn T; Cushion MT
    Eukaryot Cell; 2010 Jan; 9(1):107-15. PubMed ID: 19897737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional complementation of the yeast P-type H-ATPase, PMA1, by the Pneumocystis carinii P-type H-ATPase, PCA1.
    Grigore D; Meade JC
    J Eukaryot Microbiol; 2006; 53(3):157-64. PubMed ID: 16677337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Saccharomyces cerevisiae oxidosqualene-lanosterol cyclase: a chemistry-biology interdisciplinary study of the protein's structure-function-reaction mechanism relationships.
    Wu TK; Chang CH; Liu YT; Wang TT
    Chem Rec; 2008; 8(5):302-25. PubMed ID: 18956480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanistic insights into oxidosqualene cyclizations through homology modeling.
    Schulz-Gasch T; Stahl M
    J Comput Chem; 2003 Apr; 24(6):741-53. PubMed ID: 12666166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interactions of oxidosqualene cyclase (Erg7p) with 3-keto reductase (Erg27p) and other enzymes of sterol biosynthesis in yeast.
    Taramino S; Valachovic M; Oliaro-Bosso S; Viola F; Teske B; Bard M; Balliano G
    Biochim Biophys Acta; 2010 Feb; 1801(2):156-62. PubMed ID: 19879375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quinuclidine inhibitors of 2,3-oxidosqualene cyclase-lanosterol synthase: optimization from lipid profiles.
    Brown GR; Hollinshead DM; Stokes ES; Clarke DS; Eakin MA; Foubister AJ; Glossop SC; Griffiths D; Johnson MC; McTaggart F; Mirrlees DJ; Smith GJ; Wood R
    J Med Chem; 1999 Apr; 42(7):1306-11. PubMed ID: 10197973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Affinity labeling of vertebrate oxidosqualene cyclases with a tritiated suicide substrate.
    Abe I; Bai M; Xiao XY; Prestwich GD
    Biochem Biophys Res Commun; 1992 Aug; 187(1):32-8. PubMed ID: 1520315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism-based inhibitors and other active-site targeted inhibitors of oxidosqualene cyclase and squalene cyclase.
    Abe I; Zheng YF; Prestwich GD
    J Enzyme Inhib; 1998 Sep; 13(6):385-98. PubMed ID: 9825303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.